Nishi Rampal, M.D.
Senior Vice President, Clinical Development
Nishi brings over 20 years of clinical expertise coupled with extensive experience in the pharmaceutical and biotechnology industries with a track record of successful execution and leadership in rare disease drug development, spanning neurology, rheumatology, dermatology, and hematology. Over the course of her career in industry, she has led programs resulting in successfully global approvals including UPLINZA® (inebilizumab-cdon), a groundbreaking treatment for neuromyelitis optica spectrum disorder and and the first successful registrational trial in IgG4-RD. She also lead the ULTOMIRIS (ravulizumab-cwvz) myasthenia gravis program. Prior to Eliem, Nishi was the Executive Director Clinical Development at Horizon Therapeutics, where she was the global lead on the development and strategy for UPLINZA. Prior to Amgen, Dr. Rampal was a Medical Director Clinical Development at Alexion Pharmaceuticals.
Dr Rampal completed her neurology residency at the Yale School of Medicine and her neurophysiology and epilepsy fellowship at Columbia University, and is double board certified with past academic appointments at Yale University, Columbia University, and Mount Sinai Icahn Schools of Medicine.
With each step we advance our novel science to reach our patients. Together we Climb to a brighter future.